新辅助化疗在晚期卵巢癌治疗中的意义  

Clinical study of applying neoadjuvant chemotherapy in advanced ovarian cancer

作　　者：金向明[1] 陈萍[1] 

机构地区：[1]宁夏医科大学附属医院,宁夏银川750004

出　　处：《宁夏医学杂志》2009年第12期1133-1134,F0003,共3页Ningxia Medical Journal

摘　　要：目的探讨新辅助化疗在治疗晚期卵巢癌中的临床意义。方法选择采用肿瘤细胞减灭术+化疗综合治疗的Ⅲ、Ⅳ期卵巢癌患者45例,其中新辅助化疗组20例,先期手术组25例做对照研究。结果新辅助化疗组化疗有效率55.0%,腹水消失率56.3%。新辅助化疗组和先期手术组手术最佳减灭率分别为65.0%和32.0%(P<0.05)。中位生存时间分别为34个月和28个月,两组间生存率比较,差异无统计学意义(P>0.05)。结论对先期手术预计不能达到满意肿瘤减灭术或不能进行手术的晚期卵巢癌患者,新辅助化疗能提高最佳减灭率,但并未延长患者的生存时间。Objective To investigate the clinical effects of neoadjuvant chemotherapy in the advanced ovarian cancer.Methods Among 45 patients with Ⅲ,Ⅳ stage ovarian cancer were treated with neoadjuvant chemotherapy followed by surgery,whereas 25 cases were treated with primary surgery.Results The response rate of chemotherapy was 55% and the effective rate of extinguishing ascites was 56.3% in neoadjuvant chemotherapy group.The optimal surgery rate in neoadjuvant chemotherapy group was 65.0%,which was significantly higher than that in primary surgery group （32.0%,P0.05）.The median survival of neoadjuvant chemotherapy group （34 months） was longer than that of primary surgery group （28 months）.There were no significant differences between two groups in survival rate （P0.05）.Conclusion Neoadjuvant chemotherapy could improve the optimal surgery rate but has not prolonged survival in patients with advanced ovarian cancer.

关 键 词：晚期卵巢癌 新辅助化疗 

分 类 号：R737.31[医药卫生—肿瘤]